Compare ResMed Inc. (RMD) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Snap Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Snap Inc trades at $5.34 (market cap $9.18B). The key difference: ResMed Inc. is far larger — about 3.5× Snap Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| RMD | SNAP | |
|---|---|---|
Market Cap | $31.89B | $9.18B |
Sector | Health | Media |
52-Week High | $283.28 | $9.09 |
52-Week Low | $182.82 | $3.93 |
Enterprise Value | $31.24B | $10.75B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Snap Inc. (SNAP) trades at $5.43, down 0.73% with a bullish technical signal despite recent legal pressures. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M net income). Analyst consensus is mixed with 38% buy ratings and a $7.02 price target, while recent news highlights leadership changes and ongoing youth-safety lawsuits.
Snap presents a turnaround story with operational improvements but faces significant legal and competitive risks. The stock offers potential upside to analyst targets if execution continues, though persistent losses and regulatory challenges warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
